RapidAI receives FDA clearance for diagnostic tool that aids in assessment of brain injury

RapidAI has announced FDA clearance for Rapid Hyperdensity, a diagnostic tool that enables physicians to quickly assess the severity of injury in patients with acute conditions, such as traumatic brain injury and brain hemorrhages.

According to a company release, Rapid Hyperdensity is powered by artificial intelligence and utilizes non-contrast CT scans to assess the volume of hyperdense tissue in the brain to help physicians identify the extent of an intracerebral hemorrhage. In this way, Rapid Hyperdensity provides additional contextual data to help physicians make more rapid and informed triage and transfer decisions, a benefit for hospitals and mobile stroke units making urgent patient assessments.

“Rapid Hyperdensity helps physicians make the first of many critical decisions involved in head trauma and hemorrhagic stroke protocol,” Karim Karti, CEO of RapidAI, said in the release. “As the only comprehensive neurovascular decision support platform to offer this functionality, RapidAI aims to alleviate the enormous pressure of determining the best next course of action.”